Short-term heart rate variability is preserved in Parkinson’s disease under atomoxetine
Isabella F Orlando, Frank H Hezemans, Kamen A Tsvetanov, Rong Ye, Catarina Rua, Ralf Regenthal, Roger A Barker, Caroline H Williams-Gray, Luca Passamonti, Trevor W Robbins, James B Rowe, Claire O’Callaghan · 2026
Read Short-term heart rate variability is preserved in Parkinson’s disease under atomoxetine by Isabella F Orlando, Frank H Hezemans, Kamen A Tsvetanov, Rong Ye, Catarina Rua, Ralf Regenthal, Roger A Barker, Caroline H Williams-Gray, Luca Passamonti, Trevor W Robbins, James B Rowe, Claire O’Callaghan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13574504.txt.
Description
Isabella Orlando and co-authors test a repurposed drug's heart safety in Parkinson disease in a 2026 study. The drug, atomoxetine, raises noradrenaline levels and may help thinking and mood symptoms, but its effects on the heart in these patients were unclear. Heart rate variability, the natural beat-to-beat change, served as the safety signal.
Fifteen patients had lower variability than 22 healthy controls, and some low measures tracked with damage in a small brainstem area seen on special scans. Patients then took a single 40 milligram dose and a placebo in random order, blinded. Short-term variability did not change after the drug, and a Bayesian analysis backed that stability across many measures. The profile looks safe for the heart.
Catalog record
| CREATOR | Isabella F Orlando, Frank H Hezemans, Kamen A Tsvetanov, Rong Ye, Catarina Rua, Ralf Regenthal, Roger A Barker, Caroline H Williams-Gray, Luca Passamonti, Trevor W Robbins, James B Rowe, Claire O’Callaghan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |